Swiss National Bank Buys 109,100 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 34.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 426,600 shares of the biopharmaceutical company’s stock after acquiring an additional 109,100 shares during the period. Swiss National Bank owned about 0.17% of Lexicon Pharmaceuticals worth $315,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in Lexicon Pharmaceuticals by 71.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 13,246 shares during the period. Arizona State Retirement System increased its stake in shares of Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 16,136 shares during the period. Intech Investment Management LLC purchased a new position in shares of Lexicon Pharmaceuticals in the third quarter worth $115,000. Atom Investors LP bought a new stake in Lexicon Pharmaceuticals during the 3rd quarter valued at $122,000. Finally, XTX Topco Ltd purchased a new stake in Lexicon Pharmaceuticals during the 3rd quarter valued at $126,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $0.57 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.28 and a 1 year high of $2.45. The firm has a 50-day moving average of $0.61 and a 200 day moving average of $0.99. The company has a market cap of $140.48 million, a P/E ratio of -0.76 and a beta of 1.04.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. On average, sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LXRX shares. Piper Sandler decreased their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners reiterated a “market perform” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. StockNews.com started coverage on Lexicon Pharmaceuticals in a research note on Friday. They set a “sell” rating on the stock. Finally, Leerink Partnrs downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.67.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.